サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1550117

骨粗鬆症治療薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年

Osteoporosis Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

出版日
ページ情報
英文 157 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=142.24円
骨粗鬆症治療薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2033年
出版日: 2024年09月04日
発行: Persistence Market Research
ページ情報: 英文 157 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Researchはこのほど、世界の骨粗鬆症治療薬市場に関する広範なレポートを発行しました。当レポートでは、促進要因・動向・機会・課題などの主要な市場力学を包括的に分析し、市場構造に関する深い洞察を提供しています。

主要な洞察

  • 骨粗鬆症治療薬の市場規模（2024年）：1,390万米ドル
  • 市場予測金額（2033年）：1,890万米ドル
  • 世界市場成長率（CAGR 2024年～2033年）：3.5%

骨粗鬆症治療薬市場 - レポート範囲：

骨粗鬆症治療薬市場は、骨が弱くなり骨折のリスクが高まる骨粗鬆症の予防と治療を目的とした様々な医薬品を包括しています。これらの医薬品は、特に閉経後の女性や高齢者、その他リスクの高い人々の間で、この疾患を管理する上で極めて重要です。市場は、病院、診療所、専門薬局など多様なセグメントにサービスを提供しています。成長の原動力は、骨粗鬆症の有病率の増加、薬剤製剤の進歩、さまざまな医療現場での予防ヘルスケア対策の適用拡大です。

市場成長の促進要因：

骨粗鬆症治療薬の世界市場を牽引している主要な要因はいくつかあります。骨粗鬆症の世界の罹患率の上昇は、より多くの患者が効果的な治療オプションを必要としていることから、市場の成長を後押ししています。モノクローナル抗体や選択的エストロゲン受容体モジュレーターの開発など、薬剤製剤の技術的進歩が骨粗鬆症治療の有効性と安全性を向上させ、市場拡大にさらに拍車をかけています。さらに、骨の健康に対する意識の高まりとスクリーニング・プログラムの利用可能性の増加が需要を促進しています。研究開発の強化と革新的な治療法の導入は、さまざまな医療ニーズを持つ患者により適したソリューションを提供し、市場の成長に寄与しています。

市場抑制要因：

有望な成長が見込まれるものの、骨粗鬆症治療薬市場は、先進的な治療薬の高額な費用や、ビスフォスフォネート製剤など特定の薬剤に伴う潜在的な副作用に関する課題に直面しています。また、生活習慣の改善や非薬理学的介入など、非侵襲的であることから医療従事者によっては好まれる代替治療オプションが利用可能であることも、市場の成長を妨げる可能性があります。さらに、低リソース環境における先進的な薬剤治療へのアクセスに関する懸念は、市場拡大の課題となっています。これらの問題に対処するには、骨粗鬆症治療薬の安全性、価格、入手しやすさを改善するための研究開発への継続的な投資が必要です。

市場機会：

この市場は、患者の予後を改善する生物学的製剤や併用療法の採用拡大が大きなビジネスチャンスとなっています。徐放性製剤や注射療法などの高度なドラッグデリバリーシステムの開発は、より便利で効果的な治療オプションに対するニーズの高まりに対応するものです。新興市場におけるヘルスケア・インフラの拡大は、市場成長のための新たなチャネルを提供し、企業がより多くの患者集団にリーチし、最先端の骨粗鬆症治療へのアクセスを提供することを可能にします。戦略的パートナーシップ、患者教育プログラムへの投資、個別化医療アプローチの採用は、新たな機会を活用し、市場でのリーダーシップを維持するために不可欠です。

本レポートで扱う主要な質問

  • 世界の骨粗鬆症治療薬市場の成長を促進する主要な要因は何か？
  • 骨粗鬆症治療薬のどのような種類と製剤が様々なヘルスケア環境で採用されているか？
  • 技術の進歩は骨粗鬆症治療薬市場の競合情勢にどのような影響を与えているか？
  • 骨粗鬆症治療薬市場の主要企業はどこで、競争力を維持するためにどのような戦略を取っているのか？
  • 世界の骨粗鬆症治療薬市場における新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲 / 分類
  • 市場の定義 / 範囲 / 制限
  • 包含事項・除外事項

第3章 主要な市場動向

  • 市場に影響を与える主要な動向
  • イノベーション / 開発動向

第4章 主要な成功要因

  • 薬剤採用分析
  • 主要な規制
  • 最近の医薬品の発売 / 承認
  • パイプライン評価
  • PESTEL分析
  • バリューチェーン分析
  • 主要なプロモーション戦略：主要企業別

第5章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 薬剤別
    • 流通チャネル別
    • 国別
  • 2022年の市場シナリオ

第7章 世界の骨粗鬆症治療薬市場の需要（金額または規模、百万米ドル）分析

  • 過去の市場金額（百万米ドル）分析、2019年～2023年
  • 現在および将来の市場金額（百万米ドル）予測、2024年～2033年
    • 前年比成長動向分析
    • 絶対額の機会分析

第8章 世界の骨粗鬆症治療薬市場分析、薬剤別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（百万米ドル）の分析、薬剤別、2019年～2023年
  • 現在および将来の市場規模（百万米ドル）の分析と予測、薬剤別、2024年～2033年
    • ビスフォスフォネート
    • 副甲状腺ホルモン療法薬
    • カルシトニン
    • 選択的エストロゲン受容体モジュレーター（SERM）
    • RANKリガンド阻害剤
  • 市場の魅力分析：薬剤別

第9章 世界の骨粗鬆症治療薬市場分析、流通チャネル別

  • イントロダクション / 主要な調査結果
  • 過去の市場規模（百万米ドル）分析、流通チャネル別、2019年～2023年
  • 現在および将来の市場規模（百万米ドル）の分析と予測、流通チャネル別、2024年～2033年
    • 小売薬局
    • 病院薬局
    • オンライン販売
  • 市場の魅力分析：流通チャネル別

第10章 世界の骨粗鬆症治療薬市場分析、地域別

  • イントロダクション
  • 過去の市場規模（百万米ドル）の分析、地域別、2019年～2023年
  • 現在および将来の市場金額（百万米ドル）の分析と予測、地域別、2024年～2033年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ（MEA）
  • 市場の魅力分析：地域別

第11章 北米の骨粗鬆症治療薬市場分析

第12章 ラテンアメリカの骨粗鬆症治療薬市場分析

第13章 欧州の骨粗鬆症治療薬市場分析

第14章 東アジアの骨粗鬆症治療薬市場分析

第15章 南アジアの骨粗鬆症治療薬市場分析

第16章 オセアニアの骨粗鬆症治療薬市場

第17章 中東・アフリカ（MEA）の骨粗鬆症治療薬市場分析

第18章 市場構造分析

  • 市場分析：企業階層別
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第19章 競合分析

  • 競合ダッシュボード
  • 競合の詳細情報
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co, Inc.
    • Novartis AG
    • Amgen, Inc.
    • Novo Nordisk A/S
    • Actavis plc
    • Pfizer, Inc.
    • GlaxoSmithKline plc
    • Teva Pharmaceutical Industries Ltd
    • Enzene Biosciences Ltd
    • Theramex

第20章 使用される前提条件と頭字語

第21章 調査手法

目次
Product Code: PMRREP2983

Persistence Market Research has recently published an extensive report on the global Osteoporosis Drugs Market. This report offers a comprehensive analysis of the key market dynamics, including drivers, trends, opportunities, and challenges, providing deep insights into the market structure.

Key Insights:

  • Osteoporosis Drugs Market Size (2024E): US$ 13.9 Mn
  • Projected Market Value (2033F): US$ 18.9 Mn
  • Global Market Growth Rate (CAGR 2024 to 2033): 3.5%

Osteoporosis Drugs Market - Report Scope:

The Osteoporosis Drugs Market encompasses a variety of pharmaceutical treatments aimed at preventing and treating osteoporosis, a condition characterized by weakened bones and an increased risk of fractures. These drugs are critical in managing the disease, particularly among postmenopausal women, the elderly, and others at high risk. The market serves diverse segments, including hospitals, clinics, and specialty pharmacies. Growth is driven by the increasing prevalence of osteoporosis, advancements in drug formulations, and the expanding application of preventive healthcare measures across various healthcare settings.

Market Growth Drivers:

Several key factors are driving the global Osteoporosis Drugs Market. The rising incidence of osteoporosis globally boosts the market's growth as more patients require effective treatment options. Technological advancements in drug formulations, such as the development of monoclonal antibodies and selective estrogen receptor modulators, have improved the efficacy and safety of osteoporosis treatments, further fueling market expansion. Additionally, the growing awareness of bone health and the increasing availability of screening programs drive demand. Enhanced research and development activities, along with the introduction of innovative therapies, contribute to market growth by offering more tailored solutions for patients with different medical needs.

Market Restraints:

Despite promising growth prospects, the Osteoporosis Drugs Market faces challenges related to the high costs of advanced drug treatments and potential side effects associated with certain medications, such as bisphosphonates. Market growth can be hindered by the availability of alternative treatment options, such as lifestyle modifications and non-pharmacological interventions, which may be preferred by some healthcare providers due to their non-invasive nature. Additionally, concerns about the accessibility of advanced drug treatments in low-resource settings pose challenges for market expansion. Addressing these issues requires ongoing investment in research and development to improve the safety, affordability, and accessibility of osteoporosis drugs.

Market Opportunities:

The market presents significant opportunities driven by the increasing adoption of biologic drugs and combination therapies, which offer improved patient outcomes. The development of advanced drug delivery systems, such as extended-release formulations and injectable therapies, caters to the growing need for more convenient and effective treatment options. The expansion of healthcare infrastructure in emerging markets provides new channels for market growth, allowing companies to reach a broader patient population and offer access to cutting-edge osteoporosis treatments. Strategic partnerships, investments in patient education programs, and the introduction of personalized medicine approaches are essential for capitalizing on emerging opportunities and maintaining market leadership.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the Osteoporosis Drugs Market globally?
  • Which types and formulations of osteoporosis drugs are leading the adoption in various healthcare settings?
  • How are technological advancements influencing the competitive landscape of the Osteoporosis Drugs Market?
  • Who are the key players in the Osteoporosis Drugs Market, and what strategies are they employing to stay competitive?
  • What are the emerging trends and future prospects in the global Osteoporosis Drugs Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Osteoporosis Drugs Market, including Amgen Inc., Eli Lilly and Company, and Merck & Co., focus on innovation, product differentiation, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop advanced osteoporosis treatments and explore new drug delivery systems. Collaborations with healthcare providers, research institutions, and technology developers facilitate market access and promote new product adoption. Emphasis on patient education, high-quality products, and comprehensive training programs fosters market growth and enhances brand loyalty in the evolving Osteoporosis Drugs Market landscape.

Key Companies Profiled:

  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co, Inc.
  • Novartis AG
  • Amgen, Inc.
  • Novo Nordisk A/S
  • Actavis plc
  • Pfizer, Inc.
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd
  • Enzene Biosciences Ltd
  • Theramex

Osteoporosis Drugs Market Industry Segmentation

Drug:

  • Bisphosphonates
  • Parathyroid Hormone Therapy Drugs
  • Calcitonin
  • Selective Oestrogen Receptors Modulators (SERMs)
  • RANK Ligand Inhibitors

Distribution Channel:

  • Retail Pharmacies
  • Hospital Pharmacies
  • Online Sales

Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Innovation / Development Trends

4. Key Success Factors

  • 4.1. Drug Adoption Analysis
  • 4.2. Key Regulations
  • 4.3. Recent Drug launches/ Approvals
  • 4.4. Pipeline Assessment
  • 4.5. PESTEL Analysis
  • 4.6. Value Chain Analysis
  • 4.7. Key Promotional Strategies, By Key Players

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Outlook
    • 5.1.3. Global Orthopedic Drugs & Devices market outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Increase in R&D Spending
    • 5.2.2. Growing Osteoarthritis Prevalence
    • 5.2.3. Cost of Drug
    • 5.2.4. Drug Features
    • 5.2.5. New Drug Pipeline
    • 5.2.6. Changes in Regulatory Policies
    • 5.2.7. Strategic Collaborations amongst Players
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Drug
    • 6.1.2. By Distribution Channel
    • 6.1.3. By Country
  • 6.2. 2022 Market Scenario

7. Global Osteoporosis Drugs Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

  • 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Drug

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Mn) Analysis By Drug, 2019-2023
  • 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug, 2024-2033
    • 8.3.1. Bisphosphonates
    • 8.3.2. Parathyroid Hormone Therapy Drugs
    • 8.3.3. Calcitonin
    • 8.3.4. Selective Estrogen Receptors Modulators (SERMs)
    • 8.3.5. RANK Ligand Inhibitors
  • 8.4. Market Attractiveness Analysis By Drug

9. Global Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
  • 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2033
    • 9.3.1. Retail Pharmacies
    • 9.3.2. Hospital Pharmacies
    • 9.3.3. Online Sales
  • 9.4. Market Attractiveness Analysis By Distribution Channel

10. Global Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033, By Region

  • 10.1. Introduction
  • 10.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
  • 10.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Region 2024-2033
    • 10.3.1. North America
    • 10.3.2. Latin America
    • 10.3.3. Europe
    • 10.3.4. East Asia
    • 10.3.5. South Asia
    • 10.3.6. Oceania
    • 10.3.7. Middle East and Africa (MEA)
  • 10.4. Market Attractiveness Analysis By Region

11. North America Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 11.1. Introduction
  • 11.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 11.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 11.3.1. By Country
      • 11.3.1.1. U.S.
      • 11.3.1.2. Canada
    • 11.3.2. By Drug
    • 11.3.3. By Distribution Channel
  • 11.4. Market Attractiveness Analysis
    • 11.4.1. By Country
    • 11.4.2. By Drug
    • 11.4.3. By Distribution Channel
  • 11.5. Market Trends
  • 11.6. Drivers and Restraints - Impact Analysis
  • 11.7. Key Players - Intensity Mapping
  • 11.8. Country Level Analysis & Forecast
    • 11.8.1. U.S. Osteoporosis Drugs Market Analysis
      • 11.8.1.1. Introduction
      • 11.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.1.2.1. By Drug
        • 11.8.1.2.2. By Distribution Channel
    • 11.8.2. Canada Osteoporosis Drugs Market Analysis
      • 11.8.2.1. Introduction
      • 11.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 11.8.2.2.1. By Drug
        • 11.8.2.2.2. By Distribution Channel

12. Latin America Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 12.3.1. By Country
      • 12.3.1.1. Mexico
      • 12.3.1.2. Brazil
      • 12.3.1.3. Argentina
      • 12.3.1.4. Rest of Latin America
    • 12.3.2. By Drug
    • 12.3.3. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Drug
    • 12.4.3. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Drivers and Restraints - Impact Analysis
  • 12.7. Key Players - Intensity Mapping
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. Mexico Osteoporosis Drugs Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.1.2.1. By Drug
        • 12.8.1.2.2. By Distribution Channel
    • 12.8.2. Brazil Osteoporosis Drugs Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.2.2.1. By Drug
        • 12.8.2.2.2. By Distribution Channel
    • 12.8.3. Argentina Osteoporosis Drugs Market Analysis
      • 12.8.3.1. Introduction
      • 12.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 12.8.3.2.1. By Drug
        • 12.8.3.2.2. By Distribution Channel

13. Europe Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 13.3.1. By Country
      • 13.3.1.1. Germany
      • 13.3.1.2. Italy
      • 13.3.1.3. France
      • 13.3.1.4. U.K.
      • 13.3.1.5. Spain
      • 13.3.1.6. BENELUX
      • 13.3.1.7. Russia
      • 13.3.1.8. Rest of Europe
    • 13.3.2. By Drug
    • 13.3.3. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Drug
    • 13.4.3. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Drivers and Restraints - Impact Analysis
  • 13.7. Key Players - Intensity Mapping
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Germany Osteoporosis Drugs Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.1.2.1. By Drug
        • 13.8.1.2.2. By Distribution Channel
    • 13.8.2. Italy Osteoporosis Drugs Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.2.2.1. By Drug
        • 13.8.2.2.2. By Distribution Channel
    • 13.8.3. France Osteoporosis Drugs Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.3.2.1. By Drug
        • 13.8.3.2.2. By Distribution Channel
    • 13.8.4. U.K. Osteoporosis Drugs Market Analysis
      • 13.8.4.1. Introduction
      • 13.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.4.2.1. By Drug
        • 13.8.4.2.2. By Distribution Channel
    • 13.8.5. Spain Osteoporosis Drugs Market Analysis
      • 13.8.5.1. Introduction
      • 13.8.5.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.5.2.1. By Drug
        • 13.8.5.2.2. By Distribution Channel
    • 13.8.6. BENELUX Osteoporosis Drugs Market Analysis
      • 13.8.6.1. Introduction
      • 13.8.6.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.6.2.1. By Drug
        • 13.8.6.2.2. By Distribution Channel
    • 13.8.7. Russia Osteoporosis Drugs Market Analysis
      • 13.8.7.1. Introduction
      • 13.8.7.2. Market Analysis and Forecast by Market Taxonomy
        • 13.8.7.2.1. By Drug
        • 13.8.7.2.2. By Distribution Channel

14. East Asia Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 14.3.1. By Country
      • 14.3.1.1. China
      • 14.3.1.2. Japan
      • 14.3.1.3. South Korea
    • 14.3.2. By Drug
    • 14.3.3. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Drug
    • 14.4.3. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Drivers and Restraints - Impact Analysis
  • 14.7. Key Players - Intensity Mapping
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. China Osteoporosis Drugs Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.1.2.1. By Drug
        • 14.8.1.2.2. By Distribution Channel
    • 14.8.2. Japan Osteoporosis Drugs Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.2.2.1. By Drug
        • 14.8.2.2.2. By Distribution Channel
    • 14.8.3. South Korea Osteoporosis Drugs Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 14.8.3.2.1. By Drug
        • 14.8.3.2.2. By Distribution Channel

15. South Asia Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 15.3.1. By Country
      • 15.3.1.1. India
      • 15.3.1.2. Indonesia
      • 15.3.1.3. Malaysia
      • 15.3.1.4. Thailand
      • 15.3.1.5. Rest of South Asia
    • 15.3.2. By Drug
    • 15.3.3. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug
    • 15.4.3. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Drivers and Restraints - Impact Analysis
  • 15.7. Key Players - Intensity Mapping
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. India Osteoporosis Drugs Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.1.2.1. By Drug
        • 15.8.1.2.2. By Distribution Channel
    • 15.8.2. Indonesia Osteoporosis Drugs Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.2.2.1. By Drug
        • 15.8.2.2.2. By Distribution Channel
    • 15.8.3. Malaysia Osteoporosis Drugs Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.3.2.1. By Drug
        • 15.8.3.2.2. By Distribution Channel
    • 15.8.4. Thailand Osteoporosis Drugs Market Analysis
      • 15.8.4.1. Introduction
      • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 15.8.4.2.1. By Drug
        • 15.8.4.2.2. By Distribution Channel

16. Oceania Osteoporosis Drugs Market 2019-2023 and Forecast 2024-2033

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 16.3.1. By Country
      • 16.3.1.1. Australia
      • 16.3.1.2. New Zealand
    • 16.3.2. By Drug
    • 16.3.3. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Drug
    • 16.4.3. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Drivers and Restraints - Impact Analysis
  • 16.7. Key Players - Intensity Mapping
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. Australia Osteoporosis Drugs Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.1.2.1. By Drug
        • 16.8.1.2.2. By Distribution Channel
    • 16.8.2. New Zealand Osteoporosis Drugs Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 16.8.2.2.1. By Drug
        • 16.8.2.2.2. By Distribution Channel

17. Middle East and Africa (MEA) Osteoporosis Drugs Market Analysis 2019-2023 and Forecast 2024-2033

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
    • 17.3.1. By Country
      • 17.3.1.1. GCC Countries
      • 17.3.1.2. Turkey
      • 17.3.1.3. North Africa
      • 17.3.1.4. South Africa
      • 17.3.1.5. Rest of Middle East and Africa
    • 17.3.2. By Drug
    • 17.3.3. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug
    • 17.4.3. By Distribution Channel
  • 17.5. Market Trends
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Key Players - Intensity Mapping
  • 17.8. Country Level Analysis & Forecast
    • 17.8.1. GCC Countries Osteoporosis Drugs Market Analysis
      • 17.8.1.1. Introduction
      • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.1.2.1. By Drug
        • 17.8.1.2.2. By Distribution Channel
    • 17.8.2. Turkey Osteoporosis Drugs Market Analysis
      • 17.8.2.1. Introduction
      • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.2.2.1. By Drug
        • 17.8.2.2.2. By Distribution Channel
    • 17.8.3. South Africa Osteoporosis Drugs Market Analysis
      • 17.8.3.1. Introduction
      • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.3.2.1. By Drug
        • 17.8.3.2.2. By Distribution Channel
    • 17.8.4. North Africa Osteoporosis Drugs Market Analysis
      • 17.8.4.1. Introduction
      • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
        • 17.8.4.2.1. By Drug
        • 17.8.4.2.2. By Distribution Channel

18. Market Structure Analysis

  • 18.1. Market Analysis by Tier of Companies
  • 18.2. Market Share Analysis of Top Players
  • 18.3. Market Presence Analysis

19. Competition Analysis

  • 19.1. Competition Dashboard
  • 19.2. Competition Deep Dive
    • 19.2.1. Eli Lilly and Company
      • 19.2.1.1. Overview
      • 19.2.1.2. Product Portfolio
      • 19.2.1.3. Sales Footprint
      • 19.2.1.4. Key Financials
      • 19.2.1.5. SWOT Analysis
      • 19.2.1.6. Strategy Overview
        • 19.2.1.6.1. Marketing Strategy
        • 19.2.1.6.2. Product Strategy
        • 19.2.1.6.3. Channel Strategy
    • 19.2.2. F. Hoffmann-La Roche Ltd.
      • 19.2.2.1. Overview
      • 19.2.2.2. Product Portfolio
      • 19.2.2.3. Sales Footprint
      • 19.2.2.4. Key Financials
      • 19.2.2.5. SWOT Analysis
      • 19.2.2.6. Strategy Overview
        • 19.2.2.6.1. Marketing Strategy
        • 19.2.2.6.2. Product Strategy
        • 19.2.2.6.3. Channel Strategy
    • 19.2.3. Merck & Co, Inc.
      • 19.2.3.1. Overview
      • 19.2.3.2. Product Portfolio
      • 19.2.3.3. Sales Footprint
      • 19.2.3.4. Key Financials
      • 19.2.3.5. SWOT Analysis
      • 19.2.3.6. Strategy Overview
        • 19.2.3.6.1. Marketing Strategy
        • 19.2.3.6.2. Product Strategy
        • 19.2.3.6.3. Channel Strategy
    • 19.2.4. Novartis AG
      • 19.2.4.1. Overview
      • 19.2.4.2. Product Portfolio
      • 19.2.4.3. Sales Footprint
      • 19.2.4.4. Key Financials
      • 19.2.4.5. SWOT Analysis
      • 19.2.4.6. Strategy Overview
        • 19.2.4.6.1. Marketing Strategy
        • 19.2.4.6.2. Product Strategy
        • 19.2.4.6.3. Channel Strategy
    • 19.2.5. Amgen, Inc.
      • 19.2.5.1. Overview
      • 19.2.5.2. Product Portfolio
      • 19.2.5.3. Sales Footprint
      • 19.2.5.4. Key Financials
      • 19.2.5.5. SWOT Analysis
      • 19.2.5.6. Strategy Overview
        • 19.2.5.6.1. Marketing Strategy
        • 19.2.5.6.2. Product Strategy
        • 19.2.5.6.3. Channel Strategy
    • 19.2.6. Novo Nordisk A/S
      • 19.2.6.1. Overview
      • 19.2.6.2. Product Portfolio
      • 19.2.6.3. Sales Footprint
      • 19.2.6.4. Key Financials
      • 19.2.6.5. SWOT Analysis
      • 19.2.6.6. Strategy Overview
        • 19.2.6.6.1. Marketing Strategy
        • 19.2.6.6.2. Product Strategy
        • 19.2.6.6.3. Channel Strategy
    • 19.2.7. Actavis plc
      • 19.2.7.1. Overview
      • 19.2.7.2. Product Portfolio
      • 19.2.7.3. Sales Footprint
      • 19.2.7.4. Key Financials
      • 19.2.7.5. SWOT Analysis
      • 19.2.7.6. Strategy Overview
        • 19.2.7.6.1. Marketing Strategy
        • 19.2.7.6.2. Product Strategy
        • 19.2.7.6.3. Channel Strategy
    • 19.2.8. Pfizer, Inc.
      • 19.2.8.1. Overview
      • 19.2.8.2. Product Portfolio
      • 19.2.8.3. Sales Footprint
      • 19.2.8.4. Key Financials
      • 19.2.8.5. SWOT Analysis
      • 19.2.8.6. Strategy Overview
        • 19.2.8.6.1. Marketing Strategy
        • 19.2.8.6.2. Product Strategy
        • 19.2.8.6.3. Channel Strategy
    • 19.2.9. GlaxoSmithKline plc
      • 19.2.9.1. Overview
      • 19.2.9.2. Product Portfolio
      • 19.2.9.3. Sales Footprint
      • 19.2.9.4. Key Financials
      • 19.2.9.5. SWOT Analysis
      • 19.2.9.6. Strategy Overview
        • 19.2.9.6.1. Marketing Strategy
        • 19.2.9.6.2. Product Strategy
        • 19.2.9.6.3. Channel Strategy
    • 19.2.10. Teva Pharmaceutical Industries Ltd
      • 19.2.10.1. Overview
      • 19.2.10.2. Product Portfolio
      • 19.2.10.3. Sales Footprint
      • 19.2.10.4. Key Financials
      • 19.2.10.5. SWOT Analysis
      • 19.2.10.6. Strategy Overview
        • 19.2.10.6.1. Marketing Strategy
        • 19.2.10.6.2. Product Strategy
        • 19.2.10.6.3. Channel Strategy
    • 19.2.11. Enzene Biosciences Ltd
      • 19.2.11.1. Overview
      • 19.2.11.2. Product Portfolio
      • 19.2.11.3. Sales Footprint
      • 19.2.11.4. Key Financials
      • 19.2.11.5. SWOT Analysis
      • 19.2.11.6. Strategy Overview
        • 19.2.11.6.1. Marketing Strategy
        • 19.2.11.6.2. Product Strategy
        • 19.2.11.6.3. Channel Strategy
    • 19.2.12. Theramex
      • 19.2.12.1. Overview
      • 19.2.12.2. Product Portfolio
      • 19.2.12.3. Sales Footprint
      • 19.2.12.4. Key Financials
      • 19.2.12.5. SWOT Analysis
      • 19.2.12.6. Strategy Overview
        • 19.2.12.6.1. Marketing Strategy
        • 19.2.12.6.2. Product Strategy
        • 19.2.12.6.3. Channel Strategy

20. Assumptions and Acronyms Used

21. Research Methodology